Kolexia
Cariou Bertrand Endocrinologie
Cariou Bertrand
Endocrinologie
Hôpital Laennec
Saint-Herblain, France
560 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Diabète de type 2 Diabète Hypercholestérolémie Dyslipidémies Diabète de type 1 Hypoglycémie Hyperlipoprotéinémie de type II COVID-19 Obésité

Collaborateurs

Voir plus
Hadjadj Samy
Hadjadj Samy
Hôpital Hôtel-Dieu Nantes, Nantes, France
Wargny Matthieu
Wargny Matthieu
Hôpital Hôtel-Dieu Nantes, Nantes, France
Drui Delphine
Drui Delphine
Hôpital Laennec, Saint-Herblain, France
Krempf Michel
Krempf Michel
Hôpital Laennec, Saint-Herblain, France

Industries

Voir plus
Novartis
21 collaboration(s)
Dernière en 2023
Lilly
20 collaboration(s)
Dernière en 2023
Novo Nordisk
12 collaboration(s)
Dernière en 2023
Sanofi
12 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
PCSK9 inhibition protects mice from food allergy
Translational research : the journal of laboratory and clinical medicine   11 mars 2024
Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
JAMA pediatrics   05 mars 2024
Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population.
Journal of hepatology   06 février 2024
COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients
Essai Clinique (Amgen)   28 janvier 2024
NATiV3: A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
Essai Clinique (Inventiva Pharma)   24 janvier 2024
Parathyroidectomy Improves Bone Density in Women With Primary Hyperparathyroidism and Preoperative Osteopenia.
The Journal of clinical endocrinology and metabolism   28 décembre 2023
Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial Hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology   30 novembre 2023
Design of knowledge-based mechanistic model of atherosclerotic cardiovascular disease for in silico trials
ESC Congress 2023 25–28 August 2023 Amsterdam, Netherlands Abstract Supplement   09 novembre 2023
Efficacy and safety of alirocumab in children and adolescents with heterozygous familial hypercholesterolaemia inadequately controlled with statins
ESC Congress 2023 25–28 August 2023 Amsterdam, Netherlands Abstract Supplement   09 novembre 2023
Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
Diabetes, obesity & metabolism   07 novembre 2023